Kolexia
Delaloge Suzette Oncologie médicale
Delaloge Suzette
Oncologie médicale
Gustave-Roussy
Villejuif, France
612 Activités
4.8 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Carcinomes Carcinome canalaire du sein Récidive tumorale locale Tumeurs du sein triple-négatives Prédisposition génétique à une maladie Carcinome intracanalaire non infiltrant Tumeur du sein de l'homme

Collaborateurs

Voir plus
Andre Fabrice
Andre Fabrice
Gustave-Roussy, Villejuif, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Brain Etienne
Brain Etienne
Institut Curie, Saint-Cloud, France
Dalenc Florence
Dalenc Florence
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

Industries

Voir plus
KEPHREN PUBLISHING
6 collaboration(s)
Dernière en 2022
Novartis
5 collaboration(s)
Dernière en 2023
Exact Sciences France SAS
3 collaboration(s)
Dernière en 2021
Edimark
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
LIBER: Prevention of Breast Cancer by Letrozole in Post-menopausal Women Carrying a BRCA1/BRCA2 Mutation
Essai Clinique (Unicancer)   20 février 2024
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Essai Clinique (National Cancer Institute)   14 février 2024
Evaluation of the satisfaction and experiences of oncology patients and doctors using teleconsultation during the COVID-19 pandemic.
Journal of telemedicine and telecare   07 février 2024
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   01 février 2024
Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   19 janvier 2024
AMEERA-3: An Open Label Randomized Phase 2 Trial of Amcenestrant (SAR439859), Versus Endocrine Monotherapy as Per Physician's Choice in Patients With Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies
Essai Clinique (Sanofi)   11 janvier 2024
OlympiAD: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Essai Clinique (AstraZeneca)   20 décembre 2023
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Breast cancer research and treatment   19 décembre 2023
#ESMOBreast24: International breast cancer experts invite you to attend
Youtube @ European Society for Medical Oncology (ESMO)   19 décembre 2023